BR112022023438A2 - Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i - Google Patents

Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i

Info

Publication number
BR112022023438A2
BR112022023438A2 BR112022023438A BR112022023438A BR112022023438A2 BR 112022023438 A2 BR112022023438 A2 BR 112022023438A2 BR 112022023438 A BR112022023438 A BR 112022023438A BR 112022023438 A BR112022023438 A BR 112022023438A BR 112022023438 A2 BR112022023438 A2 BR 112022023438A2
Authority
BR
Brazil
Prior art keywords
treatment
signaling inhibitors
interferon type
cardiometabolic disease
type
Prior art date
Application number
BR112022023438A
Other languages
English (en)
Portuguese (pt)
Inventor
Sinibaldi Dominic
White Wendy
Smith Michael
Casey Kerry
Illei Gabor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022023438A2 publication Critical patent/BR112022023438A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022023438A 2020-05-29 2021-05-28 Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i BR112022023438A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
BR112022023438A2 true BR112022023438A2 (pt) 2022-12-20

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023438A BR112022023438A2 (pt) 2020-05-29 2021-05-28 Tratamento de doença cardiometabólica com inibidores de sinalização de interferon tipo i

Country Status (10)

Country Link
US (1) US12410254B2 (cg-RX-API-DMAC10.html)
EP (2) EP4157873A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023527054A (cg-RX-API-DMAC10.html)
KR (1) KR20230018446A (cg-RX-API-DMAC10.html)
CN (1) CN115667309A (cg-RX-API-DMAC10.html)
AU (1) AU2021279277A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022023438A2 (cg-RX-API-DMAC10.html)
CA (1) CA3183611A1 (cg-RX-API-DMAC10.html)
IL (1) IL298299A (cg-RX-API-DMAC10.html)
WO (1) WO2021239928A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3881233A4 (en) * 2018-11-15 2022-11-23 Ampel Biosolutions, LLC DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING

Also Published As

Publication number Publication date
WO2021239928A3 (en) 2022-01-27
KR20230018446A (ko) 2023-02-07
WO2021239928A2 (en) 2021-12-02
CA3183611A1 (en) 2021-12-02
CN115667309A (zh) 2023-01-31
IL298299A (en) 2023-01-01
US20240158519A1 (en) 2024-05-16
AU2021279277A1 (en) 2023-02-02
EP4566667A3 (en) 2025-09-03
JP2023527054A (ja) 2023-06-26
WO2021239928A9 (en) 2022-03-17
EP4566667A2 (en) 2025-06-11
EP4157873A2 (en) 2023-04-05
US12410254B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
JOP20220008A1 (ar) مثبطات parp1
GEP20247607B (en) Nitrile-containing antiviral compounds
CY1125163T1 (el) 2΄-υποκατεστημενα-ν6-υποκατεστημενα πουρινο νουκλεοτιδια για την θεραπεια ιων rna
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
CY1123387T1 (el) Συνδυασμος δυο αντιιικων για τη θεραπεια της ηπατιτιδας c
CO2021017845A2 (es) Proteínas multiespecíficas
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CR20220126A (es) Moduladores de sting (estimulador de genes de interferón)
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CO2022000481A2 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
MX2021012872A (es) Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2022000573A (es) Compuestos ciclicos de desoxirribonucleotido.
MX2022011475A (es) Azd1656 para el uso en el tratamiento de neumonitis y/o la miocarditis causadas por un coronavirus.
MX2022000052A (es) Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766.